<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863131</url>
  </required_header>
  <id_info>
    <org_study_id>EXG-5003-J01</org_study_id>
    <nct_id>NCT04863131</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of EXG-5003</brief_title>
  <official_title>Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujita Health University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elixirgen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fujita Health University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First in Human, randomized, placebo-controlled Phase I/II trial to evaluate the&#xD;
      safety and immunogenicity of the intradermal COVID-19 vaccine, EXG-5003 in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Local and Systemic Adverse Events</measure>
    <time_frame>Day 1 up to Day 365 post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flowcytometry assay to enumerate the frequency of T cells expressing CD3, CD4, CD8, CD62L, CD45RA, IFN-Î³, IL-4, CD107, TNF, IL-2, IL-6, CD154 (CD40L), Perforin, and Granzyme B.</measure>
    <time_frame>Day15, Day29, Day43, Day57, Day92, Day183, Day365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of T cells by Intracellular cytokine staining assays</measure>
    <time_frame>Day15, Day29, Day57,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genometric Mean Titer (GMT) of serum anti-RBD IgG</measure>
    <time_frame>Day15, Day29, Day43, Day57, Day92, Day183, Day365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of neutralizing antibody</measure>
    <time_frame>Day15, Day29, Day43, Day57, Day92, Day183, Day365</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>EXG-5003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EXG-5003</intervention_name>
    <description>COVID-19 self-replicating mRNA vaccine</description>
    <arm_group_label>EXG-5003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has provided written consent for participation&#xD;
&#xD;
          -  Age between 20 and 55&#xD;
&#xD;
          -  Has a negative nucleic acid-based test result for SARS-CoV-2&#xD;
&#xD;
          -  Has a negative antibody test result for SARS-CoV-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs and symptoms consistent with COVID-19 upon screening&#xD;
&#xD;
          -  History of COVID-19&#xD;
&#xD;
          -  Presence of uncontrolled cardiovascular, hematologic, respiratory, hepatic, renal,&#xD;
             gastrointestinal, or neuropsychiatric disease&#xD;
&#xD;
          -  Presence of diabetes mellitus&#xD;
&#xD;
          -  Presence of active autoimmune disease&#xD;
&#xD;
          -  Positive for HBc, HCV or HIV antibody&#xD;
&#xD;
          -  History of anaphylactic shock&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  Presence of active malignancy&#xD;
&#xD;
          -  Presence of lung disease (e.g., COPD, asthma)&#xD;
&#xD;
          -  Positive urine pregnancy test within 24 hours&#xD;
&#xD;
          -  Pregnant, lactating, planned pregnancy of self (if female) or partner (if male) within&#xD;
             90 days after administration of the trial drug&#xD;
&#xD;
          -  If female and premenopausal, not agreeable to contraception for 90 days after second&#xD;
             administration of the trial drug&#xD;
&#xD;
          -  If male, not agreeable to contraception for 90 days after second administration of the&#xD;
             trial drug&#xD;
&#xD;
          -  Presence of clinically relevant electrocardiogram or vital sign abnormality at&#xD;
             screening&#xD;
&#xD;
          -  Participated in a clinical trial of a drug or a medical device within 30 days or a&#xD;
             biologic within 90 days&#xD;
&#xD;
          -  Received any SARS-CoV-2 vaccine&#xD;
&#xD;
          -  Received within 90 days, or is planning to receive during the study period, an&#xD;
             immunoglobulin or blood product&#xD;
&#xD;
          -  Received within 180 days, or is planning to receive during the study period, a&#xD;
             biologic product with immunosuppressive properties&#xD;
&#xD;
          -  Received for 14 days or more within 180 days, or is planning to receive during the&#xD;
             study period, a corticosteroid&#xD;
&#xD;
          -  Deemed ineligible for the study as determined by the principal investigator or a&#xD;
             co-investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yohei Doi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujita Health University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koga</last_name>
    <phone>202-615-6004</phone>
    <email>mkoga@kmphc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohei Doi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujita Health University</investigator_affiliation>
    <investigator_full_name>Yohei Doi</investigator_full_name>
    <investigator_title>Professor and Chair of the Department of Microbiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

